Updates in chronic graft-versus-host disease management.
Am J Hematol
; 98(10): 1637-1644, 2023 10.
Article
in En
| MEDLINE
| ID: mdl-37483142
ABSTRACT
Chronic graft-versus-host disease (cGvHD) remains the most important long-term complication of allogeneic hematopoietic cell transplantation (allo-HCT), but the field has seen significant changes in the last decade. Remarkable advances in the understanding of the biological pathways of cGvHD, lead to the development of targeted therapy with novel drugs thereby minimizing the exposure to harmful corticosteroids, preserving function and mobility, preventing disability, and improving quality of life (QoL) and overall survival (OS). Steroid-refractory cGvHD management has recently experienced significant improvement since ibrutinib and ruxolitinib were approved for patients that failed at least one line of treatment and belumosudil for patients that failed two lines. These recently approved drugs will be discussed in this review, along with perspectives regarding cGVHD management and additional promising drug in development.
Full text:
1
Database:
MEDLINE
Main subject:
Hematopoietic Stem Cell Transplantation
/
Bronchiolitis Obliterans Syndrome
/
Graft vs Host Disease
Limits:
Humans
Language:
En
Year:
2023
Type:
Article